IRB Protocol Approved by Halozyme
January 18, 2019
Halozyme Therapeutics approved the phase-2 clinical trial our team has proposed, and the company is working with us to finalize the details of the sponsorship. This phase-2 trial is entitled "Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer". The primary goal of this trial is to test the utility of DCE-MRI and DWI markers for assessing the PDA stroma, the early response to stroma-directed investigational drug, PEGPH20, which is developed by Halozyme and is currently under phase-3 clinical trial.
Clinical Cancer Research manuscript accepted
December 4, 2018
Manuscript titled “Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma” was accepted by CCR. This is the first paper supported by the U24CA231858. Congratulations!
IRB Protocol Concept Presented
October 12, 2018
At PCRC SWAT Team Quarterly Meeting, Dr. Thomas Karasic presented the concept of a phase-2 clinical trial titled “Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer”. PCRC - Pancreatic Cancer Research Center- is a research institute of Abramson Cancer Center of University of Pennsylvania Health System.